SURGE Therapeutics, Inc. — Form D
SURGE Therapeutics, Inc. of CAMBRIDGE, MA, a company, filed a Form D exempt-offering notice with the SEC on 2020-12-04. The offering totals $29.6M, of which $20.6M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2020-12-04
- Form: D
- Accession: 0001834664-20-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $29.6M
- Amount sold: $20.6M
- Remaining: $9.0M
- Investors: 5
- Date of first sale: 2020-11-23
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-382313
Issuer
- Name: SURGE Therapeutics, Inc.
- CIK: 0001834664
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2016
- Address: ONE BROADWAY, 14TH FLOOR, CAMBRIDGE, MA, 02142
- Phone: 617-909-8181
Officers, directors & promoters (12)
| Name | Role | Location |
|---|
| Gary Goldberg | Director | Mullica Hill, NJ |
| Michael Goldberg | Director | Weston, CT |
| Gary Goldberg | Executive Officer | Mullica Hill, NJ |
| Michael Goldberg | Executive Officer | Weston, CT |
| Kouki S Harasaki | Director | Menlo Park, CA |
| Gary S Goldberg | Director | Cambridge, MA |
| Michael S Goldberg | Director | Cambridge, MA |
| Michael S Goldberg | Executive Officer | Cambridge, MA |
| Jason S Coloma | Director | Cambridge, MA |
| Chuck S Carignan | Executive Officer | Cambridge, MA |
| Antonio S Gualberto | Executive Officer | Cambridge, MA |
| Ali S Farahanchi | Director | Cambridge, MA |
Other filings by this issuer (1)
More